RSS

PARP Inhibitors

The recent approval of AstraZeneca/Merck’s Lynparza reflects the accelerating pace of Chinese drug approvals under the country’s new policy regime, according to data and analytics company, GlobalData. more

News

DNA Damage Response (DDR) company developing innovative treatments for cancer, Artios Pharma, has announced the completion of its Series B financing round in which it raised $84 million (£65 million). more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care more

News

The European Medicines Agency (EMA) has approved AstraZeneca and Merck’s Lynparza (olaparib) tablets as maintenance therapy for the treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. more

News

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the marketing authorisation of Lynparza (olaparib) tablets for patients with platinum-sensitive relapsed ovarian, fallopian tube, or primary perito more

News

The FDA has given the green light to an expansion of use of olaparib tablets (Lynparza) to now include the treatment of patients with certain types of breast cancer that have metastasized and whose tumours have a specific inherited genetic mutation. more

News

Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. more

News

The US Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application (sNDA) for Lynparza to be used in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. more

News

A study, from an international team of researchers, may offer hope to patients with prostate cancer as it shows that a combination therapy could potentially reduce the recurrence rate of the disease. more

News

One in five women with breast cancer could benefit from existing treatments previously thought not to be effective. more

News